Sort
10,766 grants matching “checkpoint inhibitor”
Pglyrp3 cooperates with Snail1 to mediate anti-tumor immune response in breast cancer
$40,465Mathew Sebastian · University Of Florida · F30 · FY2018 · CA
Project 1: Developing Immune Checkpoint Controlled Release Biomaterials for Caner Immunotherapy
$40,348Richard Mu · Tennessee State University · U54 · FY2021 · CA
Combining Radiation, Allogeneic Natural Killer Immunotherapy, and PD-L1 blockade in Dogs with Naturally-Occurring Melanoma
$40,288Aryana Razmara · University Of California At Davis · F30 · FY2023 · CA
Anxa2 drives the function of immune suppressive neutrophils in lung cancer
$40,193A. McGarry Houghton · Fred Hutchinson Cancer Research Center · R01 · FY2021 · CA
Finding the optimal balance of immunotherapy efficacy and toxicity.
$40,189David Eric Gerber · Ut Southwestern Medical Center · U01 · FY2021 · AI
Elucidating the distinct roles of T cell-polarized microglia in glioblastoma suppression and progression
$40,186Lizmarie Garcia-Rivera · Salk Institute For Biological Studies · F31 · FY2023 · CA
Dissecting the Role of Radiation in Regulation of MHC-I and Neoantigen Presentation
$40,139Chang Su · Duke University · F30 · FY2023 · CA
Dissecting the roles of a novel immune-checkpoint receptor complex in driving T cell dysfunction in cancers
$40,090Cassandra Gilmour · Cleveland Clinic Lerner Com-Cwru · F31 · FY2021 · CA
Characterizing and Overcoming MHC-I-Mediated Immune Evasion in Triple-Negative Breast Cancer
$40,064Dina O'Connell · Univ Of North Carolina Chapel Hill · F31 · FY2024 · CA
Identification of a targeted anti-mitotic agent that degrades Myc and specifically induces cancer cell death
$40,054Jessica Teitel · University Of Michigan At Ann Arbor · F31 · FY2023 · CA
Mechanisms of Exosome Driven Immunoregulation of Cancer Progression
$39,956Robert H Blelloch · University Of California, San Francisco · U01 · FY2022 · CA
Development of PD-L1 Proteolysis-Targeting Chimeras (PROTACs): An Innovative Cancer Drug Discovery Route
$39,917Demonta Coleman · Texas A&M University · F31 · FY2025 · CA
Targeting Sox10-low cells in drug-resistant melanoma
$39,915Sean Alexander Misek · Michigan State University · F31 · FY2019 · CA
Dissecting Early Tumor Evolution to Uncover Mechanisms of Tumor Initiation and Drug Resistance
$39,801Matthew James Ryan · University Of California, San Francisco · F31 · FY2023 · CA
Tumor Biology and Microenvironment
$39,772Kay-Uwe Wagner · Wayne State University · P30 · FY2022 · CA
A Novel Pathway Involving ATM, PP1 and I-2
$39,764Bo Xu · Southern Research Institute · R01 · FY2009 · ES
Uncovering interactions of the gut microbiome with the immune system in the context of immune checkpoint inhibitors
$39,650Jennifer Chung · University Of Connecticut Sch Of Med/Dnt · F30 · FY2020 · CA
BUBR1 in the Spindle Checkpoint and Tumor Suppression
$39,500Wei Dai · New York Medical College · R01 · FY2006 · CA
The relative impact of the Hippo and RB tumor suppressor pathways inhibition on the ovarian cancer progression
$39,492Fatmata Sesay · Virginia Commonwealth University · F31 · FY2021 · CA
Role of MYC Family Members in Driving Chemoresistance in Small Cell Lung Cancer
$39,468Eli Grunblatt · University Of Washington · F30 · FY2019 · CA
A Regulatory Checkpoint in the Pathogenesis of Inflammatory Arthritis
$39,404Christian Stehlik · Cedars-Sinai Medical Center · R01 · FY2017 · AR
Development of PD-L1 Proteolysis-Targeting Chimeras (PROTACs): An Innovative Cancer Drug Discovery Route
$39,353Demonta Coleman · Texas A&M University · F31 · FY2024 · CA
Discovery of myeloid immune features predictive of response to cancer immunotherapy in prostate cancer
$39,311Elizabeth McCarthy · University Of California, San Francisco · F30 · FY2022 · CA
Deubiquitinases in Cell Cycle Control
$39,277Michael James Emanuele · Univ Of North Carolina Chapel Hill · R01 · FY2023 · GM
Cancer Immunology and Immunotherapy Program
$39,235Keith L Knutson · Mayo Clinic Rochester · P30 · FY2024 · CA